The scope, scale, and science of biologics manufacturing is quickly evolving as new modalities enter the space and cost pressures demand innovation that impacts the cost of goods and time to market.
Cell and gene therapy treatments are creating interesting containment and control challenges in all aspects of their manufacture and supply chain.
The solvent management requirements of Oligonucleotide manufacture present a new challenge for typical therapeutic protein facilities and staff.
Recently licensed small molecule continuous processes have paved a regulatory path for biologics, and the journey has already begun with process intensification becoming the norm in several unit operations.
From leveraging existing capacity with novel new processes, to implementing new and emerging technologies, this conference will bring together experts and leaders to ensure the Biomanufacturing industry successfully navigates these novel new processes and delivers on our promise of supply of life changing medicines to patients across the globe.